Currently, a Phase III (NCT: NCT01681823) clinical trial is being carried out to test whether oral administration of PectaSol-C can improve prostate-specific antigen (PSA) kinetics in men with relapsed prostate cancer. Here, KLK3 is linked to prostate carcinoma.